Literature DB >> 19397851

Molecular imaging of prostate cancer: a concise synopsis.

Hossein Jadvar1.   

Abstract

Prostate cancer is the most common malignancy in men and continues to be a major public health problem. Imaging of prostate cancer remains particularly challenging owing to disease heterogeneity. Molecular imaging can provide unprecedented opportunities for deciphering the molecular mechanisms that are involved in the development and natural progression of prostate cancer from a localized process to the hormone-refractory metastatic disease. Such understanding will be the key for targeted imaging and therapy and for predicting and evaluating treatment response and prognosis. In this article, we review briefly the contribution of multimodality molecular imaging methods for the in vivo characterization of the pathophysiology of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19397851      PMCID: PMC2688393     

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  96 in total

Review 1.  Integrated, molecular engineering approaches to develop prostate cancer gene therapy.

Authors:  Lily Wu; Makoto Sato
Journal:  Curr Gene Ther       Date:  2003-10       Impact factor: 4.391

2.  Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.

Authors:  Beth R Pflug; Stefana M Pecher; Alisa W Brink; Joel B Nelson; Barbara A Foster
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

3.  New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors.

Authors:  Xiaobing Fan; Milica Medved; Jonathan N River; Marta Zamora; Claire Corot; Philippe Robert; Philippe Bourrinet; Martin Lipton; Rita M Culp; Gregory S Karczmar
Journal:  Magn Reson Med       Date:  2004-03       Impact factor: 4.668

4.  Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.

Authors:  Steven M Larson; Michael Morris; Ilonka Gunther; Brad Beattie; John L Humm; Timothy A Akhurst; Ronald D Finn; Yusuf Erdi; Keith Pentlow; Jon Dyke; Olivia Squire; William Bornmann; Timothy McCarthy; Michael Welch; Howard Scher
Journal:  J Nucl Med       Date:  2004-03       Impact factor: 10.057

Review 5.  The Na/I symporter (NIS): imaging and therapeutic applications.

Authors:  Ekaterina Dadachova; Nancy Carrasco
Journal:  Semin Nucl Med       Date:  2004-01       Impact factor: 4.446

6.  Intracellular visualization of prostate cancer using magnetic resonance imaging.

Authors:  Stefan Heckl; Rüdiger Pipkorn; Waldemar Waldeck; Herbert Spring; Jürgen Jenne; Claus-W von der Lieth; Heike Corban-Wilhelm; Jürgen Debus; Klaus Braun
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

7.  Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue.

Authors:  Dawn M Carnell; Rowena E Smith; Frances M Daley; Paul R Barber; Peter J Hoskin; George D Wilson; Graeme I Murray; Steven A Everett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

8.  Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.

Authors:  Denise S O'Keefe; Dean J Bacich; Warren D W Heston
Journal:  Prostate       Date:  2004-02-01       Impact factor: 4.104

9.  Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

Authors:  Eija Sutinen; Martti Nurmi; Anne Roivainen; Matti Varpula; Tuula Tolvanen; Pertti Lehikoinen; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-20       Impact factor: 9.236

Review 10.  Molecular imaging in prostate cancer.

Authors:  Jose A Karam; Ralph P Mason; Kenneth S Koeneman; Peter P Antich; Elie A Benaim; Jer-Tsong Hsieh
Journal:  J Cell Biochem       Date:  2003-10-15       Impact factor: 4.429

View more
  8 in total

1.  VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.

Authors:  Sushil Tripathi; Edouard J Trabulsi; Leonard Gomella; Sung Kim; Peter McCue; Charles Intenzo; Ruth Birbe; Ashish Gandhe; Pardeep Kumar; Mathew Thakur
Journal:  Urology       Date:  2015-10-28       Impact factor: 2.649

2.  Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.

Authors:  Robert M Taylor; Virginia Severns; David C Brown; Marco Bisoffi; Laurel O Sillerud
Journal:  Prostate       Date:  2011-07-11       Impact factor: 4.104

3.  Metabolomics: a novel approach to early and noninvasive prostate cancer detection.

Authors:  Matthew J Roberts; Horst J Schirra; Martin F Lavin; Robert A Gardiner
Journal:  Korean J Urol       Date:  2011-02-19

4.  Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

Authors:  Alessandro Ruggiero; Jason P Holland; Tvrtko Hudolin; Larissa Shenker; Anna Koulova; Neil H Bander; Jason S Lewis; Jan Grimm
Journal:  J Nucl Med       Date:  2011-09-09       Impact factor: 10.057

5.  [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.

Authors:  Bernd J Krause; Michael Souvatzoglou; Ken Herrmann; Axel W Weber; Tibor Schuster; Andreas K Buck; Roman Nawroth; Gregor Weirich; Uwe Treiber; Hans-Jürgen Wester; Sibylle I Ziegler; Reingard Senekowitsch-Schmidtke; Markus Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-30       Impact factor: 9.236

6.  Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer.

Authors:  Hossein Jadvar; Kai Chen; Ryan Park; Li-Peng Yap; Ivetta Vorobyova; Steve Swenson; Francis S Markland
Journal:  Amino Acids       Date:  2019-10-16       Impact factor: 3.520

7.  Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts.

Authors:  Isabel R Schlaepfer; L Michael Glodé; Carolyn A Hitz; Colton T Pac; Kristen E Boyle; Paul Maroni; Gagan Deep; Rajesh Agarwal; Scott M Lucia; Scott D Cramer; Natalie J Serkova; Robert H Eckel
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

8.  Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer.

Authors:  Niki Marie Zacharias; Christopher McCullough; Sriram Shanmugavelandy; Jaehyuk Lee; Youngbok Lee; Prasanta Dutta; James McHenry; Linda Nguyen; William Norton; Lawrence W Jones; Pratip K Bhattacharya
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.